Rovelizumab

• CAT Number: I041527
• CAS Number: 339086-79-2
• Purity: ≥95%

Rovelizumab is a humanized monoclonal leukointegrin antibody. Rovelizumab is a monoclonal antibody directed against the CD11/CD18 cell adhesion proteins. Rovelizumab can be used for research of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI) and stroke[1].
Rovelizumab binds CD18 and has activity against CD18-integrin complexes including the CD11b-CD18 heterodimer[2].

Reference

[1]. Jones R. Rovelizumab (ICOS Corp). IDrugs. 2000 Apr;3(4):442-6.
 [Content Brief]

[2]. Qualls JE, et al. A double agent in cancer: stopping macrophages wounds tumors. Nat Med. 2010 Aug;16(8):863-4.
 [Content Brief]